Literature DB >> 15049620

Effective asymmetric synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benzo[e]indol-4-one (CBI).

David B Kastrinsky1, Dale L Boger.   

Abstract

A short, asymmetric synthesis of the 1,2,9,9a-tetrahydrocyclopropa[c]benzo[e]indol-4-one (CBI) analogue of the CC-1065 and duocarmycin alkylation subunits is detailed that employs an effective enzymatic desymmetrization reaction of prochiral diol 12 using a commercially available Pseudomonas sp. lipase. The optically active monoacetate (S)-13 is furnished in exceptional conversions (88%) and optical purity (99% ee) and serves as an intermediate for the preparation of either enantiomer of CBI. Similarly, the Pseudomonas sp. lipase resolved the racemic intermediate 19, affording advanced intermediates of CBI in good conversions and optical purity (99% ee), and provided an alternative approach to the preparation of optically active CBI derivatives.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15049620     DOI: 10.1021/jo035465x

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  13 in total

1.  Synthesis and evaluation of duocarmycin SA analogs incorporating the methyl 1,2,8,8a-tetrahydrocyclopropa[c]oxazolo[2,3-e]indol-4-one-6-carboxylate (COI) alkylation subunit.

Authors:  Kristopher E Boyle; Karen S MacMillan; David A Ellis; James P Lajiness; William M Robertson; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-02-02       Impact factor: 2.823

2.  A five-membered lactone prodrug of CBI-based analogs of the duocarmycins.

Authors:  Mika Uematsu; Daniel M Brody; Dale L Boger
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

3.  Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.

Authors:  Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Douglas Brown; George A Vielhauer; Dale L Boger
Journal:  J Med Chem       Date:  2013-05-10       Impact factor: 7.446

4.  Asymmetric synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benzo[e]indol-4-one (CBI).

Authors:  James P Lajiness; Dale L Boger
Journal:  J Org Chem       Date:  2010-12-30       Impact factor: 4.354

5.  Synthesis and characterization of a cyclobutane duocarmycin derivative incorporating the 1,2,10,11-tetrahydro-9H-cyclobuta[c]benzo[e]indol-4-one (CbBI) alkylation subunit.

Authors:  James P Lajiness; Dale L Boger
Journal:  J Am Chem Soc       Date:  2010-10-06       Impact factor: 15.419

6.  A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.

Authors:  Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Scott J Weir; George A Vielhauer; Dale L Boger
Journal:  J Med Chem       Date:  2012-06-12       Impact factor: 7.446

7.  Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation.

Authors:  James P Lajiness; William M Robertson; Irene Dunwiddie; Melinda A Broward; George A Vielhauer; Scott J Weir; Dale L Boger
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

8.  A unique class of duocarmycin and CC-1065 analogues subject to reductive activation.

Authors:  Wei Jin; John D Trzupek; Thomas J Rayl; Melinda A Broward; George A Vielhauer; Scott J Weir; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2007-11-17       Impact factor: 15.419

Review 9.  Fundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065.

Authors:  Karen S MacMillan; Dale L Boger
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

10.  Dinuclear zinc-catalyzed asymmetric desymmetrization of acyclic 2-substituted-1,3-propanediols: a powerful entry into chiral building blocks.

Authors:  Barry M Trost; Sushant Malhotra; Takashi Mino; Naomi S Rajapaksa
Journal:  Chemistry       Date:  2008       Impact factor: 5.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.